Regentis Biomaterials, a US and Israel-based developer of hydrogels for human tissue regeneration, has raised $10m in its series C round from a consortium including Netherlands-based industrial group Royal DSM.
The $10m will be used to develop Regentis’s European presence and expand its ongoing clinical efforts of GelrinC, a biodegradable implant that enhances growth of articular cartilage in damaged knee joints.
Also in the syndicate are venture capital firms Crossroad Fund, Medica Venture Partners, SCP-Vitalife and the Technion Investment Opportunities Fund, the investment fund of the Technion – Israel Institute of Technology.
In April 2008, Regentis won the Best Incubator Company of the year award having been established at Technion Seed and subsequently raising $7.5m from Vitalife – one of Technion Seed’s partners, which had invested the initial funding in the company – and other investors.
Technion Seed is a seed-stage investment firm, owned jointly by four top-tier Venture Capital funds – Vertex Venture Capital, Battery Ventures (US-based), SCP-Vitalife and ProSeed – and the Technion Research & Development Foundation.